Acorda Therapeutics (Acorda Therapeutics) Days Sales Outstanding

: 35.16 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

Acorda Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $14.6 Mil. Acorda Therapeutics's Revenue for the three months ended in Dec. 2023 was $38.0 Mil. Hence, Acorda Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 35.16.

The historical rank and industry rank for Acorda Therapeutics's Days Sales Outstanding or its related term are showing as below:

ACORQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.59 Med: 42.32 Max: 52.59
Current: 40.78

During the past 13 years, Acorda Therapeutics's highest Days Sales Outstanding was 52.59. The lowest was 23.59. And the median was 42.32.

ACORQ's Days Sales Outstanding is ranked better than
78.4% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 72.185 vs ACORQ: 40.78

Acorda Therapeutics's Days Sales Outstanding declined from Dec. 2022 (41.40) to Dec. 2023 (35.16).

Acorda Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Acorda Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

43.17

50.44

52.59

47.51

48.35

Acorda Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																41.40	47.26	34.72	41.76	35.16

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acorda Therapeutics Days Sales Outstanding Distribution

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Days Sales Outstanding falls into.

Acorda Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Acorda Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (13.866	+	17.298)	/	2 )	/	117.633	*	365
=	15.582					/	117.633	*	365
=	48.35

Acorda Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (11.977	+	17.298)	/	2 )	/	37.985	*	365 / 4
=	14.6375					/	37.985	*	365 / 4
=	35.16

Acorda Therapeutics (OTCPK:ACORQ) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Acorda Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Acorda Therapeutics (Acorda Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Executives

Thomas M. Burns	director	2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen	officer: CEO and President	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser	officer: Chief Financial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff	officer: General Counsel	11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem	officer: Chief Commercial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales	officer: Interim PAO & PFO	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman	officer: Exec V Pres, Gen Cnsl & Sec	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: Exec. VP-Commercial Dvlpmnt	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence	officer: Chief Financial Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank	officer: Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc.	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich	10 percent owner	C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123